Market Overview

UPDATE: Deutsche Bank Reiterates on Alexion Pharmaceuticals Ahead of Asfotase Alfa Launch

Share:
Related ALXN
Leerink Presents: Your 2017 Biopharma Catalyst Tracker
15 Biggest Mid-Day Gainers For Friday
Alexion submits Soliris marketing application in Japan for myasthenia gravis; shares up 1% after hours (Seeking Alpha)

In a report published Monday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating on Alexion Pharmaceuticals (NASDAQ: ALXN), and raised the price target from $125.00 to $205.00.

In the report, Deutsche Bank noted, “The next new product launch for Alexion is Asfotase Alfa for severe Hypophosphatasia (HPP). Our deep dive into the drug suggests the market is bigger vs. street expectations. We also updated our Soliris & expense assumptions to more accurately reflect company guidance. We believe incidence is greater than literature suggests & model 1/25,000 in US & 1/50,000 ex-US of severe pediatric HPP.”

Alexion Pharmaceuticals closed on Friday at $163.63.

Latest Ratings for ALXN

DateFirmActionFromTo
Mar 2017NomuraInitiates Coverage OnBuy
Dec 2016OppenheimerInitiates Coverage OnPerform
Dec 2016Morgan StanleyDowngradesOverweightEqual-Weight

View More Analyst Ratings for ALXN
View the Latest Analyst Ratings

Posted-In: Deutsche Bank Robyn KarnauskasAnalyst Color Price Target Analyst Ratings

 

Related Articles (ALXN)

View Comments and Join the Discussion!